So why not construct results data that show primary end point efficacy of the whole group, but also provide the results for those who have been on the drug for 42 days. Certainly the calculations could be done.

Read More: https://investorshangout.com/post/view?id=597...z6ejSkZZy9

For what its worth - maybe the power of the larger sample is important to the outcome.